AstraZeneca PLC (AZN.L) Thursday said interim results from the Phase 3 ECHO study evaluating Calquence in combination with standard-of-care chemoimmunotherapy showed a statistically significant and clinically meaningful improvement in progression-free survival in patients with mantle cell lymphoma (MCL).MCL is typically an aggressive and rare form of non-Hodgkin lymphoma (NHL), often diagnosed as a late-stage disease.AstraZeneca said the trial will continue to assess the secondary endpoint of overall survival (OS), as OS data were not mature at the time of the analysis.

阿斯利康公司（AstraZeneca PLC）周四表示，评估Calquence联合标准护理化学免疫疗法的3期ECHO研究的中期结果显示，套细胞淋巴瘤（MCL）患者的无进展生存率有统计学意义和临床意义的改善。MCL通常是一种侵袭性且罕见的非霍奇金淋巴瘤（NHL），通常被诊断为晚期疾病。阿斯利康表示，该试验将继续评估总生存期（OS）的次要终点，因为分析时OS数据尚不成熟。

However, a trend was observed in favour of Calquence plus chemoimmunotherapy for the OS..

然而，观察到有利于Calquence加化学免疫疗法治疗OS的趋势。。

The safety and tolerability of Calquence was consistent with its known safety profile, and no new safety signals were identified. For comments and feedback contact: editorial@rttnews.comBusiness News

Calquence的安全性和耐受性与其已知的安全性一致，并且没有发现新的安全信号。如需评论和反馈，请联系：editorial@rttnews.comBusiness新闻

Biotech Stocks Facing FDA Decision In April 2024

2024年4月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision in March 2024

2024年3月美国食品和药物管理局决定生物技术股

Biotech Stocks Facing FDA Decision In November 2023

2023年11月美国食品和药物管理局决定生物技术股